Proactive Investors - Run By Investors For Investors

IXICO to provide data analytics and neuroimaging services to a late-stage Huntington's programme

“The announcement emphasises our partner-of-choice status in neurodegenerative data analytics and our capabilities across all stages of clinical development," said chief executive Giulio Cerroni
brain scan
Huntington's disease is an inherited disorder that results in the death of brain cells

IXICO PLC (LON:IXI) said it will provide data analytics and neuroimaging services to a late-stage programme for people with the degenerative brain disorder Huntington's disease.

Its expertise will be used in what’s called an extension study to allow people living with Huntington's to continue to contribute to the search for a treatment for the condition. IXICO’s involvement will generate a further £500,000 in revenues.

WATCH: IXICO to support late phase clinical research programme in Huntington's disease

“The announcement emphasises our partner-of-choice status in neurodegenerative data analytics and our capabilities across all stages of clinical development," said chief executive Giulio Cerroni.

In a note to clients, analysts at ‘house’ broker Shore Capital commented: “The extension is further evidence of IXICO’s momentum in Huntington’s disease, having agreed four new contracts for the condition in its last financial year, including a £9.1mln agreement for a pivotal Phase III trial announced in September.”

In afternoon trading, IXICO shares eased back after hitting an early session high of 32p, losing a penny at 29.50p.

 -- Adds analyst comment, share price --

View full IXI profile View Profile

IXICO PLC Timeline

Related Articles

Alliance
April 05 2019
Chief executive Peter Butterfield said the company has started 2019 well-positioned for growth after a strong performance in 2018.
copd radiograph
April 02 2019
City broker Peel Hunt reckons the recent approvals “support the top-line forecasts in our model that should see Circassia achieve EBITDA positivity in 2020”
scientists in a lab
January 30 2019
The technology first drew the attention of ChemioCare CEO Pedro Lichtinger years ago while he oversaw Pfizer's global primary care business

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use